Much of the world is grappling with a mental health crisis — with soaring rates of depression and anxiety. Last year, the startup Gate Neurosciences emerged with a novel approach. While the Carmel, Indiana–based company is focused on synaptic plasticity like many other contemporary CNS companies, it diverges in its strategy. Rather than using a…
Study suggests mGlyR could be a promising antidepressant target
A study published in Science has revealed important information about a brain receptor known as mGlyR, which could be a potential antidepressant target. An abbreviation of “metabotropic glycine receptor,” mGlyR is highly active in the brain’s medial prefrontal cortex (mPFC). Abnormal activity in the brain region is associated with depression. Formerly known as GPR158, mGlyR…